Adversarial Injection · Idecabtagene Vicleucel (Abecma; bb2121; BMS-986229; BLA 125736; no conventional CAS — autologous living cell therapy; NIOSH HD Category 1; [ONE-HUNDRED-FIRST MECHANISM CLASS in Glyphward 674-attack portfolio — FIRST BCMA (B-CELL MATURATION ANTIGEN; TNFRSF17; CD269; TNFRSF13A) DIRECTED AUTOLOGOUS CAR-T CELL THERAPY EVER FDA APPROVED (BLA 125736 MARCH 26 2021; R/R MULTIPLE MYELOMA ≥3 PRIOR LINES); BCMA BIOLOGY: TNFRSF17 (TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 17; CD269; ALSO CALLED TNFRSF13A IN SOME OLDER NOMENCLATURE); 18 AA EXTRACELLULAR DOMAIN (ECD) — SMALLEST TNFR SUPERFAMILY MEMBER; TYPE I TRANSMEMBRANE PROTEIN; EXPRESSED ~95%+ OF MATURE PLASMA CELLS INCLUDING MALIGNANT MM PLASMA CELLS; B-CELL LINEAGE SPECIFIC (ABSENT ON NAÏVE B CELLS EXCEPT LATE TRANSITIONAL; PRESENT PLASMA CELLS); NATURAL LIGANDS: APRIL (TNFSF13; A PROLIFERATION-INDUCING LIGAND) + BAFF (TNFSF13B; B-CELL ACTIVATING FACTOR) → BCMA SIGNALING → NF-κB + PI3K/AKT + MAPK → MM PLASMA CELL SURVIVAL + PROLIFERATION + ANTI-APOPTOTIC; BCMA SHEDDING: γ-SECRETASE CLEAVES BCMA ECD → SOLUBLE BCMA (sBCMA) → DECOY ANTIGEN ABSORBS CAR-T CELLS → REDUCED EFFICACY IN HIGH sBCMA PATIENTS; bb2121 CAR CONSTRUCT: J6M0-DERIVED ANTI-BCMA scFv (VH4-34/Vλ6 GERMLINE; HUMANIZED; Kd ~2 nM FOR BCMA ECD; EPITOPE ON BCMA CYSTEINE-RICH DOMAIN LOOP 2) → (G4S)4 LINKER → VL + VH IN scFv FORMAT; CD8α HINGE (41 AA) + CD8α TRANSMEMBRANE DOMAIN (23 AA) + 4-1BB INTRACELLULAR COSTIMULATORY DOMAIN (42 AA; TRAF2/3/5 BINDING → NF-κB CANONICAL + AP-1 → T-CELL SURVIVAL + MEMORY PERSISTENCE; PREFERRED OVER CD28 FOR MYELOMA CAR-T: MORE CENTRAL MEMORY-BIASED; LESS RAPID EXHAUSTION) + CD3ζ SIGNALING DOMAIN (ITAM × 3; ZAP70/LAT SIGNALING); LENTIVIRAL VECTOR: VSV-G PSEUDOTYPED SELF-INACTIVATING (SIN) LV; EF1α PROMOTER; bb2121 CAR TRANSGENE; DISTINCT FROM PRIOR BCMA APPROACHES: BELANTAMAB MAFODOTIN (61ST CLASS; ADC; AFUCOSYLATED IgG1 + MMAF; ADC MECHANISM) + TECLISTAMAB (66TH CLASS; BCMA×CD3 BISPECIFIC T-CELL ENGAGER; OFF-THE-SHELF; WEEKLY SC DOSING; BISPECIFIC MECHANISM) — bb2121 IS AUTOLOGOUS CAR-T: PATIENT'S OWN T CELLS; SINGLE INFUSION; ANTIGEN-RECOGNITION + MEMORY PERSISTENCE; KARMMA PHASE 2 (NCT03361748): R/R MM ≥3 PRIOR LINES (PROTEASOME INHIBITOR + IMMUNOMODULATORY DRUG + CD38 AB REQUIRED); 450×10⁶ CAR+ T CELLS DOSE: ORR 81.5%; CR 39.3%; MRD-NEG 26.1%; MEDIAN FOLLOW-UP 13.3 MONTHS: mDOR 10.9 MONTHS; GRADE 3+ CRS 4.6%; GRADE 3+ ICANS 3.3%; BLA 125736 APPROVED MARCH 26 2021 (BMS/BLUEBIRD BIO); SUBSEQUENTLY BMS SOLE HOLDER (BLUEBIRD ONCOLOGY EXIT 2021); NIOSH HD CATEGORY 1 ANTINEOPLASTIC; NO CONVENTIONAL CAS; OSHA NO PEL; NO ACGIH TLV; NO NIOSH REL; BLA 125736 → CORITY NULL; VELOCITYEHS NULL; EHS INSIGHT NULL; BCMA TNFRSF17 18 AA ECD ABSENT; J6M0 scFv Kd ABSENT; 4-1BB NF-κB ABSENT; KARMMA ABSENT; NIOSH HD CAT 1 ABSENT ALL EHS DATABASES]) · First BCMA TNFRSF17 Autologous CAR-T + J6M0 scFv + KarMMa MM · Attack #674

Idecabtagene Vicleucel (Abecma; bb2121; BLA 125736; [ONE-HUNDRED-FIRST MECHANISM CLASS — FIRST BCMA (TNFRSF17; CD269; 18 AA ECD) DIRECTED AUTOLOGOUS CAR-T (J6M0 scFv Kd ~2 nM; CD8α HINGE+TM; 4-1BB TRAF2/3/5→NF-κB; CD3ζ ITAM×3; VSV-G SIN LENTIVIRAL) EVER FDA APPROVED (BLA 125736 MARCH 26 2021); KARMMA R/R MM ORR 81.5% CR 39.3% MRD-NEG 26.1%; BMS; NIOSH HD CATEGORY 1; NO CONVENTIONAL CAS]) — Bristol Myers Squibb Company Summit NJ (BLA 125736 holder post-bluebird oncology exit; no CAS → displayed BLA 125736), Lonza Pharma & Biotech Houston TX (CAR-T manufacturing bb2121 lentiviral transduction expansion; no CAS → displayed BLA 125736), and Memorial Sloan Kettering Cancer Center New York NY (KarMMa trial site; major myeloma program; no CAS → displayed BLA 125736) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return (no conventional CAS — cell therapy) + BCMA TNFRSF17 18 aa ECD Absent + J6M0 scFv Kd Absent + KarMMa Results Absent: AI Prompt Injection via EHS Monitor Report AI

Idecabtagene vicleucel (Abecma; bb2121; BLA 125736; NIOSH HD Category 1) is the one-hundred-first mechanism class in the Glyphward adversarial portfolio — the first BCMA (TNFRSF17; CD269; 18 amino acid extracellular domain — smallest TNFR superfamily member) directed autologous CAR-T cell therapy (J6M0-derived scFv Kd ~2 nM; 4-1BB lentiviral) ever FDA approved (BLA 125736 March 26 2021) — a unique immunologic mechanism and occupational hazard profile entirely absent from Cority, VelocityEHS, and EHS Insight for BLA 125736.

Idecabtagene Vicleucel as One-Hundred-First Mechanism Class: First BCMA-Directed Autologous CAR-T Ever

Idecabtagene vicleucel (Abecma; bb2121; BLA 125736) represents the one-hundred-first mechanism class in the Glyphward portfolio: the first BCMA (B-cell maturation antigen; TNFRSF17; CD269) directed autologous CAR-T cell therapy ever FDA approved (BLA 125736 March 26 2021; R/R multiple myeloma after ≥3 prior lines including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody). BCMA ANTIGEN BIOLOGY: BCMA (TNFRSF17/CD269) is a type I transmembrane glycoprotein in the TNF receptor superfamily with a uniquely small extracellular domain (ECD): only 18 amino acids (QKCSPSDTDSSICSRPPS) in the mature form after signal peptide cleavage — the smallest ECD of any TNFR superfamily member; the ECD contains a single cysteine-rich domain (CRD) with two disulfide bonds (Cys7-Cys15; Cys9-Cys17 by structural analogy) critical for ligand binding; BCMA LIGANDS AND SIGNALING: natural ligands APRIL (a proliferation-inducing ligand; TNFSF13; affinity Kd ~0.01-0.1 nM) and BAFF (B-cell activating factor; TNFSF13B; lower affinity for BCMA) bind BCMA CRD → receptor trimerization → TRAF3/TRAF6 recruitment → canonical NF-κB (IκBα phosphorylation → RelA/p50 nuclear translocation → survival gene transcription: BCL-2, BCL-XL, MCL-1) + non-canonical NF-κB (NIK→IKKα → p100→p52/RelB) + PI3K/AKT + MAPK/ERK → plasma cell survival + anti-apoptotic; BCMA EXPRESSION IN MYELOMA: expressed ~95-100% of primary MM plasma cells (IHC; flow cytometry); B-cell lineage-restricted — naïve B cells lack BCMA; pre-plasmablast/plasmablast transition → BCMA upregulation; normal bone marrow plasma cells express BCMA (risk for on-target off-tumor hematologic toxicity — B-cell aplasia long-term); BCMA SHEDDING — KEY THERAPEUTIC CHALLENGE: γ-secretase complex (PSEN1/PSEN2 catalytic subunit; nicastrin; APH-1; PEN-2) cleaves BCMA juxtamembrane stalk → releases soluble BCMA (sBCMA) into serum; sBCMA ~100-3000 ng/mL in MM patients; sBCMA serves as a decoy antigen — absorbs CAR-T cells and bispecific T-cell engagers → reduced effector-antigen engagement → inferior therapeutic outcomes in high-sBCMA patients; γ-secretase inhibitors (GSI) can block BCMA shedding → upregulate surface BCMA → potentiate BCMA-targeting therapies (clinical evaluation ongoing); bb2121 CAR CONSTRUCT DETAIL: J6M0 scFv ORIGIN: humanized anti-BCMA antibody (J6M0 parent from GSK/bluebird collaboration; originally GSK2857916 program; VH4-34/Vλ6 germline framework; three CDRs engineered to bind BCMA CRD epitope at loop 2 region; Kd ~2 nM for recombinant human BCMA ECD by SPR/BLI; high specificity: no binding to other TNFR family members; BCMA epitope distinct from APRIL/BAFF binding site — allows simultaneous APRIL/BAFF binding and J6M0 binding [non-blocking for natural ligands]); scFv FORMAT: VH-linker-VL (vs some designs: VL-linker-VH); (G4S)4 flexible linker (15 aa); scFv expressed as single polypeptide chain; CD8α HINGE (41 AA): connects scFv to transmembrane domain; poly-proline helix structure; resists proteolytic cleavage; positions scFv at correct distance from cell surface for BCMA engagement (~30-50 Å from membrane); CD8α TRANSMEMBRANE (23 AA): single-pass; anchors CAR in T-cell membrane; 4-1BB COSTIMULATORY (42 AA): CD137; TRAF binding domain (TRAF2/TRAF3/TRAF5 → canonical NF-κB → RelA/p65→BCL-2/BCL-XL → T-cell survival; TRAF1 → NF-κB2/NIK → non-canonical NF-κB → T-cell memory); AKT/mTOR (rapamycin-sensitive; drives memory T-cell metabolism and longevity); JNK/p38 (AP-1 → cytokine transcription); 4-1BB RATIONALE FOR MYELOMA: CD28 costimulation (used in axicabtagene) → faster expansion but earlier exhaustion; 4-1BB → slower expansion, central memory enrichment (CCR7+CD45RO+ Tcm; TCF1+), better long-term persistence → preferred for myeloma CAR-T where durable responses required; CD3ζ (113 AA; ITAM×3): ZAP70 (via ITAM pTyr) → LAT → PLCγ (→IP3→Ca²+→NFAT) + DAG (→PKCθ→NF-κB) → full T-cell activation; LENTIVIRAL VECTOR: VSV-G pseudotyped (broad tropism; hepatocyte potential concern → mitigated by systemic dilution in CAR-T context); self-inactivating (SIN) design: U3 promoter deletion in LTR → no replication-competent retrovirus; EF1α ubiquitous promoter → constitutive CAR expression; copy number 1-3 integrations per T cell; integration site analysis monitors for insertional oncogenesis; MANUFACTURING: bluebird bio bb2121 process at their own facility (originally; subsequently contracted to Lonza and other CDMOs post-bluebird oncology exit); APHERESIS: leukapheresis → leukocyte collection bag → cryoshipped; T-CELL ACTIVATION: anti-CD3/CD28 bead activation (Dynabead MACSiBead) + IL-2 (first activation) → LV transduction (Day 1-2); EXPANSION: IL-2/IL-15 containing media (10-14 days) → CD3/CD4/CD8/CAR phenotype monitoring (flow cytometry); RELEASE TESTING: CAR+ T-cell %; CD4:CD8 ratio; sterility; mycoplasma; endotoxin; identity; KARMMA PHASE 2 (NCT03361748): open-label; R/R MM; ELIGIBILITY: ≥3 prior therapies (proteasome inhibitor, immunomodulatory drug, anti-CD38 antibody); primary endpoint ORR by IMWG criteria; DOSE: 150-450×10⁶ CAR+ T cells; at 450×10⁶ dose (recommended dose for approval): ORR 81.5%; sCR (stringent CR) 26.7%; CR 39.3%; MRD-negative complete response (by next-generation flow; sensitivity 10⁻⁵): 26.1%; mDOR 10.9 months; median follow-up 13.3 months; Grade 3+ CRS (ASTCT): 4.6%; Grade 3+ ICANS: 3.3%; BLA 125736 APPROVAL: FDA approved March 26 2021 (BMS/bluebird bio co-sponsors); bluebird bio announced exit from oncology August 2021 (split into two companies: bluebird bio [gene therapy: sickle cell/beta-thalassemia] + 2seventy bio [oncology: bb2121 → acquired by BMS]); BMS (Bristol-Myers Squibb) holds BLA 125736 as of 2seventy bio/BMS arrangement; NONE OF THESE — BCMA TNFRSF17 18 AA ECD STRUCTURE, APRIL/BAFF SIGNALING, GAMMA-SECRETASE BCMA SHEDDING, J6M0 scFv Kd ~2 nM EPITOPE, 4-1BB TRAF2/3/5 NF-κB MEMORY, KARMMA ORR 81.5% CR 39.3% MRD-NEG 26.1%, LENTIVIRAL BIOSAFETY PROFILE — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR BLA 125736 (NO CONVENTIONAL CAS).

Surface 1 — Bristol Myers Squibb Company Summit NJ BLA 125736 Holder AI

At Bristol Myers Squibb Company 1 Celgene Way Summit NJ 07901 (BMS IDECABTAGENE CONTEXT: Bristol-Myers Squibb Company (NYSE: BMY) holds BLA 125736 for idecabtagene vicleucel (Abecma) following the acquisition of the oncology program from bluebird bio; BMS is the commercial and regulatory sponsor post-2seventy bio arrangement; US commercial launch April 2021; indicated for R/R MM after ≥4 prior lines (revised label) including a proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody; COMMERCIAL: Abecma administered at authorized treatment centers (ATCs); single infusion; lymphodepletion (fludarabine 30 mg/m²/day × 3 + cyclophosphamide 300 mg/m²/day × 3) → idecabtagene infusion Day 0; OCCUPATIONAL HAZARD AT BMS SUMMIT NJ: NIOSH HD Category 1 antineoplastic (living cell therapy; genetically modified T cells); no conventional CAS (autologous living cell therapy); BLA 125736 is the regulatory identifier; employees in commercial, regulatory, and pharmacovigilance roles at BMS Summit NJ handle imetelstat (imetelstat is a different drug) — BCMA-directed CAR-T program data and materials; EMPLOYEE: 51M BMS Summit NJ VP hematology/oncology idecabtagene vicleucel Abecma bb2121 BLA 125736 R/R MM 17yr; CORITY NULL: BLA 125736 query → no record; no CAS entry (cell therapy); NIOSH HD Category 1 absent; BCMA TNFRSF17 18 aa ECD absent; J6M0 scFv Kd absent; 4-1BB NF-κB absent; KarMMa ORR 81.5% absent; CRS/ICANS management absent).

Surface 2 — Lonza Pharma & Biotech Houston TX bb2121 CAR-T Manufacturing CDMO AI

At Lonza Pharma & Biotech Houston TX 77025 (Texas Medical Center campus vicinity; LONZA IDECABTAGENE MANUFACTURING CONTEXT: Lonza's Houston Texas facility (Lonza Pharma & Biotech; TMC campus) provides CAR-T cell therapy CDMO manufacturing services including: apheresis leukocyte receipt and thaw; T-cell activation (anti-CD3/CD28 bead or soluble activator + cytokine cocktail); lentiviral vector transduction (VSV-G SIN LV; BSL-2 containment; classified recombinant DNA work; PPE: N95 + double gloves + gown + eye protection; spill kit for LV containment; no open LV handling per biosafety protocol); T-cell expansion (IL-2/IL-15 media; rocking bioreactor or static flask; 10-14 day culture); CAR+ T-cell release testing (flow cytometry: anti-CD3/anti-BCMA CAR staining; CD4:CD8 ratio; viability DAPI); cryopreservation (CS10 media: DMSO 10% + dextran 40; CryoMed controlled-rate freezer; LN2 vapor storage ≤−130°C); drug substance fill (infusion bag fill; final QC); OCCUPATIONAL HAZARDS AT LONZA HOUSTON: LV transduction (VSV-G pseudotyped SIN LV; BSL-2 recombinant DNA; BMBL 5th ed.; IBC review required); DMSO (CS10 solvent; percutaneous absorption penetrant; potential carry-through of antineoplastic residue); LN2 (liquid nitrogen vapor; enclosed-space asphyxiation risk; cryogenic burn); cytokines (IL-2/IL-15; immunologically active; potential systemic effects on inadvertent injection/aerosolization); bb2121 product (NIOSH HD Cat 1 antineoplastic living cell therapy; closed manufacturing system; PPE per USP 800 principles); EMPLOYEE: 45F Lonza Houston TX CAR-T manufacturing specialist bb2121 idecabtagene lentiviral BCMA scFv expansion 14yr; VELOCITYEHS NULL: BLA 125736 → no record; NIOSH HD Category 1 absent; LV transduction biosafety absent; BCMA scFv absent; 4-1BB lentiviral absent; KarMMa absent; DMSO cryopreservation absent).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY KarMMa Trial Site AI

At Memorial Sloan Kettering Cancer Center 1275 York Ave New York NY 10065 (MSK IDECABTAGENE CONTEXT: MSK is a KarMMa Phase 2 (NCT03361748) enrolling site and authorized treatment center (ATC) for Abecma commercial use; MSK myeloma program: one of the largest MM programs in the US; KarMMa PROTOCOL AT MSK: patient ELIGIBILITY review (MM ≥3 prior lines; proteasome inhibitor-exposed + IMiD-exposed + anti-CD38 antibody-exposed); APHERESIS: leukapheresis at MSK apheresis center; leukocyte collection → cryoshipment to bb2121 manufacturing; typically 4-6 weeks manufacturing turnaround; BRIDGING THERAPY: MM treatment during manufacturing to control disease (daratumumab, carfilzomib, lenalidomide, or dexamethasone — bridging per investigator discretion); LYMPHODEPLETION (MSK inpatient or outpatient with daily monitoring): fludarabine 30 mg/m²/day × 3 days (Days −4 to −2) + cyclophosphamide 300 mg/m²/day × 3 days (Days −4 to −2); INFUSION DAY 0: idecabtagene vicleucel (cryopreserved; LN2 shipper; 37°C waterbath thaw at bedside; IV over 30 minutes); MONITORING: CRS (ASTCT grading; Grade 1-2: tocilizumab 8 mg/kg; Grade 3: tocilizumab + dexamethasone; Grade 4: ICU; Grade 3+ rate 4.6%); ICANS (CART-TANGO score; anti-seizure prophylaxis; dexamethasone); cytokine panel (IL-6, ferritin, CRP q8h in first 72h); CAR-T EXPANSION: peripheral blood CAR-T monitoring by ddPCR or flow cytometry; peak expansion Day 7-14; PHARMACY ROLE: Abecma (NIOSH HD Cat 1 antineoplastic) → thaw → IV preparation; closed system; double gloves + gown per MSK antineoplastic handling policy; EHS INSIGHT NULL (NO CAS): BLA 125736 → "no record — standard biological handling protocol"; NIOSH HD Cat 1 absent; BCMA mechanism absent; KarMMa ORR 73% absent; J6M0 scFv absent; 4-1BB NF-κB absent; EMPLOYEE: 39M MSK New York NY multiple myeloma attending physician KarMMa bb2121 BLA 125736 CAR-T 11yr).

Integrating Glyphward into Idecabtagene Vicleucel AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every idecabtagene vicleucel BLA 125736 monitoring data ingestion point — before Cority at Bristol Myers Squibb Summit NJ, before VelocityEHS at Lonza Pharma & Biotech Houston TX, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL [no conventional CAS]; no ACGIH TLV; no NIOSH REL) [10 pts]; ONE-HUNDRED-FIRST MECHANISM CLASS — FIRST BCMA TNFRSF17 DIRECTED AUTOLOGOUS CAR-T EVER FDA APPROVED (BLA 125736 March 26 2021; J6M0 scFv Kd ~2 nM; CD8α hinge+TM; 4-1BB TRAF2/3/5→NF-κB; CD3ζ ITAM×3; VSV-G SIN lentiviral; KarMMa ORR 81.5% CR 39.3% MRD-neg 26.1%; BMS) [5 pts]; BMS Summit NJ + Lonza Houston TX + MSK New York NY [3 pts]; BCMA 18 aa ECD absent; J6M0 scFv absent; KarMMa absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_idecabtagene(bla: str, exposure_context: str) -> dict:
    """Scan idecabtagene vicleucel with one-hundred-first-class first-bcma-car-t context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "bla": bla,
                "cas": None,  # autologous cell therapy — no conventional CAS
                "exposure_context": exposure_context,
                "context": "one_hundred_first_class_first_bcma_tnfrsf17_cd269_directed_autologous_car_t_j6m0_scfv_kd_2nm_cd8a_hinge_tm_4_1bb_traf235_nfkb_cd3z_itam3_vsvg_sin_lentiviral_karmma_orr_815pct_cr_393_mrd_neg_261_bms_bla_125736"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, one_hundred_first_class,
    #                    first_bcma_car_t, j6m0_scfv_confirmed,
    #                    four_1bb_nfkb, karmma_orr_815pct

if __name__ == "__main__":
    r = asyncio.run(scan_idecabtagene(
        bla="125736",
        exposure_context="car_t_manufacturing_lentiviral_transduction_bcma_scfv_expansion"
    ))
    print(r)
    # {'hd_category': 1, 'one_hundred_first_class': True,
    #  'first_bcma_car_t': True, 'j6m0_scfv_confirmed': True,
    #  'four_1bb_nfkb': True, 'karmma_orr_815pct': True}